The consumer health business model leaves little room for US marketers to maneuver in light of the Trump administration's Chinese import tariffs, and OTC industry representatives are dismayed their products haven't been shielded as the tariff plan moves forward.
Trump's Chinese Import Tariff Hike Could Take Toll On Consumer Health Sector
Low margins, limited supplier alternatives leave little room for OTC drug marketers in the US to maneuver as ingredients continue to be subject to Chinese import tariffs.
More from China
• By
Haleon now holds 88% of its China OTC joint venture after acquiring a larger stake in the business from its local partners.
• By
APAC health agencies such as WHO and Thailand's FDA are on board with the self-care agenda, and see it as crucial to achieving universal health coverage.
• By
Haleon highlighted consistent market share gains in China as it reported third-quarter results.
• By
Joint venture business which markets Haleon's OTC drug brands in China will soon be 88% owned by the UK-based firm.
More from Asia
• By
Self-care industry representatives from GSCF/AESGP, Bayer and Opella stress the seriousness of the global climate crisis at the 2024 GSCF, APSMI, TSMIA Joint Congress in Bangkok, Thailand, and also share iniatives that are attempting to deal with this crisis, for example replacing PVC in medicine blister packs with more easily recyclable materials.
• By
GSCF research shows that self-care already saves the Asia Pacific region more than $30bn a year in healthcare system costs. To realize higher gains, health literacy, Rx-to-OTC switch and digitalization need to be leveraged, according to the EU-ASEAN Business Council.
• By
APAC health agencies such as WHO and Thailand's FDA are on board with the self-care agenda, and see it as crucial to achieving universal health coverage.